Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Fred Saad(Centre Hospitalier de l’Université de Montréal), Eric J. Small(CancerCare Manitoba), Karim Fizazi(Institut Gustave Roussy), Paul de Souza(St. George Hospital), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Charles J. Ryan(University of Minnesota), Youn C. Park(Janssen (United States)), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Tomasz M. Beer(Oregon Health & Science University), Thian Kheoh(Janssen (United States)), Hendrik Van Poppel(University of Tübingen), Scott North, John D. Hainsworth(Vanderbilt University Medical Center), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Howard I. Scher(Kantonsspital Baselland Standort Bruderholz), Yves Fradet(Université Laval), Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Evan Y. Yu(University of Washington), Thomas W. Flaig(University of Colorado Denver), Neal D. Shore(Carolina Urologic Research Center), Matthew R. Smith(Harvard University), Margaret K. Yu(Janssen (Belgium)), Peter F.A. Mulders(Radboud University Nijmegen), Arturo Molina(Janssen (United States)), Mary B. Todd(Janssen (United States)), Mary-Ellen Taplin(Dana-Farber Brigham Cancer Center), Celestia S. Higano(University of Washington), Thomas W. Griffin(Janssen (Belgium)), Joan Carles(Vall d'Hebron Hospital Universitari)

European Urology

March 6, 2014

Cited by 273

Related Papers

|Nature Genetics|2019|4.4k

|Cell|2015|3.6k

|New England Journal of Medicine|2017|3.4k

|New England Journal of Medicine|2014|3k

|New England Journal of Medicine|2012|2.8k